Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs
- 12 September 2002
- journal article
- Published by Springer Nature in Oncogene
- Vol. 21 (41) , 6249-6254
- https://doi.org/10.1038/sj.onc.1205793
Abstract
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. Oncogene also publishes 8 Reviews issues a year, on a broad range of topics.Keywords
This publication has 21 references indexed in Scilit:
- D1 in G2Cell Cycle, 2002
- Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicityOncogene, 2001
- The Radioresistance to Killing of A1–5 Cells Derives from Activation of the Chk1 PathwayPublished by Elsevier ,2001
- Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugsJournal of Clinical Investigation, 2000
- The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01Journal of Biological Chemistry, 2000
- Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugsOncogene, 1999
- Requirement for p53 and p21 to Sustain G 2 Arrest After DNA DamageScience, 1998
- Cell-cycle control and its watchmanNature, 1996
- Paclitaxel (Taxol)New England Journal of Medicine, 1995
- P53, cell cycle control and apoptosis: Implications for cancerCancer and Metastasis Reviews, 1995